Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients.
brachytherapy
liver
local control
metastases
outcome
radiotherapy
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Dec 2021
13 Dec 2021
Historique:
received:
02
12
2021
accepted:
10
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Local ablative treatments have emerged as a promising treatment strategy for patients with oligometastatic disease. Among others, interstitial brachytherapy (iBT) is an upcoming treatment option for unresectable liver metastases. We report the feasibility and oncologic outcome of iBT of oligometastatic liver metastases performed in patients with limited tumor burdens in a high-volume center. Patients undergoing iBT between August 2017and March 2019 were included. A retrospective analysis of patient outcomes and treatment complications was performed. Patients treated for metastatic colorectal carcinoma (CRC) were compared to other histologies. A total of 141 iBT procedures were performed in 106 patients (male:52; female:54) and 244 liver metastases. Overall, 51% (54/106) of patients had a diagnosis of metastatic CRC. The median follow-up was 9 months, and overall survival (OS) was 92.3% at 6 months and 76.3% at 12 months. Local-relapse-free survival (LRFS) was 88.4% at 6 months and 71.5% at 12 months, with a significant difference between patients with CRC (84.1% and 50.6%) versus other histologies (92.4% and 92.4%,
Identifiants
pubmed: 34944869
pii: cancers13246250
doi: 10.3390/cancers13246250
pmc: PMC8699459
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncol Lett. 2018 Jun;15(6):8717-8722
pubmed: 29928323
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Radiat Oncol. 2019 Oct 26;14(1):184
pubmed: 31655620
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
J Clin Oncol. 2021 Aug 20;39(24):2643-2646
pubmed: 34133197
Diagn Interv Radiol. 2019 Sep;25(5):360-367
pubmed: 31348004
J Contemp Brachytherapy. 2019 Aug;11(4):329-336
pubmed: 31523233
World J Urol. 2013 Dec;31(6):1525-30
pubmed: 23132612
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Hepatobiliary Pancreat Dis Int. 2015 Oct;14(5):530-8
pubmed: 26459730
Radiother Oncol. 2011 Aug;100(2):314-9
pubmed: 21497930
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Cardiovasc Intervent Radiol. 2020 Feb;43(2):284-294
pubmed: 31797103
Anticancer Res. 2012 Dec;32(12):5453-8
pubmed: 23225451
J Vasc Interv Radiol. 2017 May;28(5):672-682
pubmed: 27645463
Anticancer Res. 2020 Aug;40(8):4281-4289
pubmed: 32727755
Brachytherapy. 2021 Jul-Aug;20(4):936-947
pubmed: 34001415
Strahlenther Onkol. 2016 May;192(5):288-96
pubmed: 26923394
J Clin Oncol. 2009 Aug 1;27(22):3677-83
pubmed: 19470929
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):479-85
pubmed: 20304566
Radiother Oncol. 2018 May;127(2):246-252
pubmed: 29510865
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):172-9
pubmed: 20056348
Cardiovasc Intervent Radiol. 2009 Sep;32(5):937-45
pubmed: 19472000
Radiat Oncol. 2020 Mar 9;15(1):60
pubmed: 32151255
Anticancer Res. 2019 May;39(5):2501-2508
pubmed: 31092445
Radiat Oncol. 2021 May 6;16(1):86
pubmed: 33957941
J Vasc Interv Radiol. 2012 May;23(5):618-26
pubmed: 22525020
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Rofo. 2014 Jun;186(6):606-12
pubmed: 24407711
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376151
Strahlenther Onkol. 2021 Jul;197(7):601-613
pubmed: 33884441
Brachytherapy. 2019 Jan - Feb;18(1):63-70
pubmed: 30385116
Radiother Oncol. 2020 Jul;148:157-166
pubmed: 32388150
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810244
Cardiovasc Intervent Radiol. 2016 Dec;39(12):1716-1721
pubmed: 27435581
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301